Dr. John Cush RheumNow
7 years ago
JAMA study shows inconsistencies and inaccuracies in EMR documentation of ROS and PE findings compared to observer audible recorded observations - study of 9 ED Residents, 30 pt encounters each, total of 180 ED patients. https://t.co/PttGYvgCue
As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.
Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d
After a few clinic no-shows, our clinic partner discussions lapsed into a discussion of clinics, especially bad clinics. Amidst the cussing and discussing of clinic experience, my partner, Dr. Dao, threw out the phrase, “clinic exorcism”! What a great title for a different kind of blog.
When clinic operations and operators are truly bad, who you gonna call? Not Clinic Busters. Think about clinic exorcisms designed to eradicate potentially
Dr. John Cush RheumNow
7 years ago
Question for Rheumatologists - How do you scoreboard your performance as a Rheumatologist?
Dr. John Cush RheumNow
7 years ago
Systemic sclerosis is associated with an increased cancer risk. A cohort of 1727 SSc pts showed an increased cancer SIR of 2.15 (CI 1.84‐2.49). Most common cancers were breast, melanoma, hematological & lung. CA risk higher w/ RNAP III Ab, CCB Rx & ILD https://t.co/q5iTRI91Ng
Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.
Dr. John Cush RheumNow
7 years ago
FDA issues warning against the use of higher doses of Imodium (loperamide) - has been associated with "serious heart problems and deaths with much higher than the recommended doses of loperamide". https://t.co/UxPn6F6BL0
A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control.
Dr. John Cush RheumNow
7 years ago
Altoona Arthritis Center and Dr. Alan Kivitz praised in the news for their unique blend of patient care and clinical trials research https://t.co/9kGLBhwzsn
Dr. John Cush RheumNow
7 years ago
Renal Review on treating asymptomatic hyperuricemia in CKD patients finds very few studies demonstrating renal protective effects w/ ULT w/ an abnormal uric acid. (this is without consideration of degree of CKD or hyperuricemia) https://t.co/nKo018lb6v
Dr. John Cush RheumNow
7 years ago
Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
Dr. John Cush RheumNow
7 years ago
The RheumNow Podcast is up – Should you Believe in Vitamin D or Rituximab? Watch it on RheumNow>> https://t.co/bX5u9KcKYz or listen to the podcast on iTunes or SoundCloud>> https://t.co/MxDcIyej3L
Dr. John Cush RheumNow
7 years ago
142 pts with ANCA-Associated Vasculitis were studied for lipid levels - Lipid levels increased during remission in newly diagnosed AAV and PR3+ AAV (not MPO or relapsing pts). Lipid levels correlated w/ ESR but not other inammatory markers. https://t.co/9UgUXv6BhI
Dr. John Cush RheumNow
7 years ago
29 Patients with MDA-5+ Dermatomyositis compliated by ILD were treated with high‐dose steroids, tacrolimus, and IV cyclophosphamide +/- Plasmapheres. 6 mos survival was better (89% and 33%, respectively, P < 0.0001) compared to 15 pts not treated https://t.co/utPiaQlUZF
